Stock Track | Stevanato Group Shares Surge on Q3 Earnings Beat and Revenue Outlook

Stock Track

Nov 05, 2024

Shares of Stevanato Group S.p.A. (NYSE: STVN), a leading producer of glass vials for COVID-19 vaccines, soared over 5% on Monday after the company reported better-than-expected third-quarter revenue and provided an optimistic full-year revenue outlook.

While the company's Q3 adjusted earnings of €0.12 ($0.13) per share narrowly missed analysts' estimates of €0.13, its revenue of €277.9 million surpassed the consensus estimate of €274.4 million. Stevanato attributed the revenue growth to strong demand for its pharmaceutical products.

For the full year 2024, Stevanato expects revenue in the range of €1.09 billion to €1.11 billion, in line with analysts' expectations of €1.09 billion. However, the company slightly lowered its adjusted earnings per share guidance to €0.47-€0.49, compared to the previous outlook of €0.48-€0.50.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1186717979"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1186717979\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1186717979?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-05 22:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186717979","market":"us","top_or_hot":-1,"title":"Stock Track | Stevanato Group Shares Surge on Q3 Earnings Beat and Revenue Outlook","media":"Stock Track","content":"<p>Shares of Stevanato Group S.p.A. (NYSE: STVN), a leading producer of glass vials for COVID-19 vaccines, soared over 5% on Monday after the company reported better-than-expected third-quarter revenue and provided an optimistic full-year revenue outlook.</p>\n\n<p>While the company's Q3 adjusted earnings of €0.12 ($0.13) per share narrowly missed analysts' estimates of €0.13, its revenue of €277.9 million surpassed the consensus estimate of €274.4 million. Stevanato attributed the revenue growth to strong demand for its pharmaceutical products.</p>\n\n<p>For the full year 2024, Stevanato expects revenue in the range of €1.09 billion to €1.11 billion, in line with analysts' expectations of €1.09 billion. However, the company slightly lowered its adjusted earnings per share guidance to €0.47-€0.49, compared to the previous outlook of €0.48-€0.50.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Stevanato Group Shares Surge on Q3 Earnings Beat and Revenue Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Stevanato Group Shares Surge on Q3 Earnings Beat and Revenue Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-05 22:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Stevanato Group S.p.A. (NYSE: STVN), a leading producer of glass vials for COVID-19 vaccines, soared over 5% on Monday after the company reported better-than-expected third-quarter revenue and provided an optimistic full-year revenue outlook.</p>\n\n<p>While the company's Q3 adjusted earnings of €0.12 ($0.13) per share narrowly missed analysts' estimates of €0.13, its revenue of €277.9 million surpassed the consensus estimate of €274.4 million. Stevanato attributed the revenue growth to strong demand for its pharmaceutical products.</p>\n\n<p>For the full year 2024, Stevanato expects revenue in the range of €1.09 billion to €1.11 billion, in line with analysts' expectations of €1.09 billion. However, the company slightly lowered its adjusted earnings per share guidance to €0.47-€0.49, compared to the previous outlook of €0.48-€0.50.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"STVN","symbol_name":"Stevanato Group S.p.A.","start_time":0,"source_url":"","article_id":"1186717979","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186717979","pubTimestamp":1730818222,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Stevanato Group S.p.A. , a leading producer of glass vials for COVID-19 vaccines, soared over 5% on Monday after the company reported better-than-expected third-quarter revenue and provided an optimistic full-year revenue outlook.While the company's Q3 adjusted earnings of 0.12  per share narrowly missed analysts' estimates of 0.13, its revenue of 277.9 million surpassed the consensus estimate of 274.4 million. Stevanato attributed the revenue growth to strong demand for its pharmaceut","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"STVN":"Stevanato Group S.p.A."},"translate_title":"Stevanato Group股价因第三季度盈利超出预期和收入前景而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STVN":1},"content_text":"Shares of Stevanato Group S.p.A. (NYSE: STVN), a leading producer of glass vials for COVID-19 vaccines, soared over 5% on Monday after the company reported better-than-expected third-quarter revenue and provided an optimistic full-year revenue outlook.\nWhile the company's Q3 adjusted earnings of €0.12 ($0.13) per share narrowly missed analysts' estimates of €0.13, its revenue of €277.9 million surpassed the consensus estimate of €274.4 million. Stevanato attributed the revenue growth to strong demand for its pharmaceutical products.\nFor the full year 2024, Stevanato expects revenue in the range of €1.09 billion to €1.11 billion, in line with analysts' expectations of €1.09 billion. However, the company slightly lowered its adjusted earnings per share guidance to €0.47-€0.49, compared to the previous outlook of €0.48-€0.50.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}